Key result
Pediatric MASLD linked to greater risk of youth-onset type 2 diabetes and adverse liver outcomes.
Why the study?
The rise in pediatric obesity has driven an increase in MASLD, which poses a public health concern due to potential progression to advanced liver disease and cardiometabolic comorbidities.
This review highlights the growing public health concern of pediatric MASLD in children with obesity, emphasizing its association with cardiometabolic comorbidities and outlining future research directions.
The global rise in pediatric obesity has paralleled an alarming increase in metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). MASLD in children represents a significant public health concern due to its potential progression to advanced liver disease and its association with a myriad of cardiometabolic comorbidities. This review elucidates the risk and consequences of pediatric MASLD in the population of children with obesity. It also identifies critical research gaps and outlines future directions for the prevention, diagnosis, and treatment of pediatric MASLD.
No takes yet. Share an insight, caveat, or question.
Resthie R. Putri (2025) conducted a review in Pediatric obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent comorbidity of childhood obesity that significantly increases the risk of youth-onset type 2 diabetes and adverse liver outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: